Amylyx’s ALS Drug Lacks ‘Confirmatory Evidence’ Needed To Support Approval On Single Study, FDA Says

New analyses on individual responders, survival and biomarker data are not independent evidence of AMX0035’s clinical effect in ALS, agency says in advisory committee briefing document. However, FDA’s framing of the issues, with an emphasis on regulatory flexibility and unmet medical need, could sway a favorable recommendation in its second panel review.

Tree in tree
Amylyx's ALS drug is getting a second chance with an FDA advisory committee. • Source: Shutterstock

US Food and Drug Administration reviewers appear unpersuaded that Amylyx Pharmaceuticals, Inc. has provided the confirmatory evidence needed to support approval of its amyotrophic lateral sclerosis drug AMX0035 on the basis of a single Phase II trial.

However, the agency’s framing of the background and issues – emphasizing regulatory flexibility in the context of a rare, serious...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers